Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis

Modern Rheumatology

Volumn 27, Issue 1, 2017, Pages 110-114

  Cestelli, Valentina ^a   Manfredi, Andreina ^a   Sebastiani, Marco ^a   Praino, Emanuela ^b   Cannarile, Francesca ^c   Giuggioli, Dilia ^a   Ferri, Clodoveo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bosentan; CSURI; Iloprost; Microangiopathy; Systemic sclerosis; Videocapillaroscopy

Indexed keywords

BOSENTAN; ILOPROST; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

ADULT; ARTICLE; CAPILLAROSCOPIC SKIN ULCER RISK INDEX; CAPILLAROSCOPY; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE DURATION; DRUG EFFICACY; FEMALE; FINGER ULCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANEURYSM; MICROANGIOPATHY; MICROVASCULATURE; NAILFOLD VIDEOCAPILLAROSCOPY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK FACTOR; SCLERODERMA; SCORING SYSTEM; SYSTEMIC SCLEROSIS; AGED; ANGIOSCOPY; CAPILLARY; COMBINATION DRUG THERAPY; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CAPILLARIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ILOPROST; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84976907258     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2016.1192761     Document Type: Article

References (39)

1. Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F, et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients’ population and review of the literature. Autoimm Rev. 2014;13:1026–34.
2. Carpentier Ph, Maricq Hr., Microvasculature in systemic sclerosis. Rheum Dis Clin North Am. 1990;16:75–91.
3. Barsotti S, Stagnaro C, Della Rossa A., Systemic sclerosis:a critical digest of the recent literature. Clin Exp Rheumatol. 2015;33:S3–14.
4. Herrick A., Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am. 2008;34:89–114.
5. Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev. 2015;14:314–22.
6. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953.
7. Wall LB, Stern PJ., Nonoperative treatment of digital ischemia in systemic sclerosis. J Hand Surg Am. 2012;37:1907–9.
8. D’Amelio P, Cristofaro MA, D’Amico L, Veneziano L, Roato I, Sassi F, et al. Iloprost modulates the immune response in systemic sclerosis. BMC Immunol. 2010;11:62.
9. Shah P, Murray AK, Moore TL, Herrick AL., Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy:a pilot study. J Rheumatol. 2011;38:2079–80.
10. Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis:prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.
11. Seibold JR, Matucci Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65(suppl ii):90.
12. Kahaleh MB., Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 1991;34:978–83.
13. Balbir-Gurman A, Braun-Moscovici Y., Scleroderma–new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13–24.
14. Agard C, Carpentier PH, Mouthon L, Clerson P, Gressin V, Bérezné A, et al. Use of bosentan for digital ulcers related to systemic sclerosis:a real-life retrospective French study of 89 patients treated since specific approval. Scand J Rheumatol. 2014;43:398–402.
15. Lee P, Leung FY, Alderdice C, Armstrong SK., Nailfold capillary microscopy in the connective tissue diseases:a semiquantitative assessment. J Rheumatol. 1983;10:930–8.
16. Cutolo M, Sulli A, Pizzorni C, Accardo S., Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27:155–60.
17. Sulli A, Secchi ME, Pizzorni C, Cutolo M., Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis. 2008;67:885–7.
18. Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D, et al. Capillaroscopic skin ulcer risk index:a new prognostic tool for digital skin ulcer development in Systemic Sclerosis Patients. Arthritis Rheum. 2009;61:688–94.
19. Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M, et al. Predictive role of capillaroscopy skin ulcer risk index in systemic sclerosis:a multicentre validation study. Ann Rheum Dis. 2012;71:67–70.
20. Sebastiani M, Manfredi A, Lo Monaco A, Praino E, Riccieri V, Grattagliano V, et al. Capillaroscopic skin Ulcers Risk Index (CSURI) calculated with different videocapillaroscopy devices:how its predictive values change. Clin Exp Rheumatol. 2013;31:S115–17.
21. Manfredi A, Sebastiani M, Carraro V, Iudici M, Bocci M, Vukatana G, et al. Prediction risk chart for scleroderma digital ulcers:a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemoreol Microcirculat. 2015;59:133–43.
22. Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis:an American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55.
23. Grassi W, De Angelis R., Capillaroscopy:questions and answers. Clin Rheumatol. 2007;26:2009–16.
24. Maricq HR, Spencer-Green G, Leroy EC., Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 1976;61:862–70.
25. Ingegnoli F, Ardoino I, Boracchi P, Cutolo M,; EUSTAR co-authors. Nailfold capillaroscopy in systemic sclerosis:data from the EULAR scleroderma trials and research (EUSTAR) database. Microvasc Res. 2013;89:122–8.
26. Andrade LE, Gabriel Júnior A, Assad RL, Ferrari AJ, Atra E., Panoramic nailfold capillaroscopy:a new reading method and normal range. Semin Arthritis Rheum. 1990;20:21–31.
27. Altman DG., Practical statistics for medical research. London:Chapman & Hall; 1991.
28. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.
29. Wigley FM, Seibold JR, Wise RA, Mccloskey DA, Dole WP., Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19:1407–14.
30. Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol. 2012;31:1723–5.
31. Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A., Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol. 2013;40:40–5.
32. Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, et al. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol. 2014;41:881–6.
33. Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, et al. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients:an in vitro study. Clin Exp Rheumatol. 2015;33:S148–52.
34. Dupuis J, Hoeper MM., Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31(2):407–15.
35. Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary hypertension:does selectivity matter? Eur Heart J. 2008;29:1936–48.
36. Price LC, Howard LS., Endothelin receptor antagonists for pulmonary arterial hypertension:rationale and place in therapy. Am J Cardiovasc Drugs. 2008;8(3):171–85.
37. Dhillon S., Bosentan–a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs. 2009;69(14):2005–24.
38. Fishman AP., Pulmonary hypertension–beyond vasodilator therapy. N Engl J Med. 1998;338:321–2.
39. Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, et al. Systemic sclerosis patients with and without pulmonary arterial hypertension:a nailfold capillaroscopy study. Rheumatology. 2013;52:1525–8.